• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: ADHD market to reach $13.9B by 2024

Report: ADHD market to reach $13.9B by 2024

September 7, 2016
CenterWatch Staff

The market for attention deficit hyperactivity disorder (ADHD) across the seven major markets (7MM) of the U.S., France, Germany, Italy, Spain, the U.K. and Japan, is set to experience an increase from approximately $6.1 billion in 2014 to $13.9 billion by 2024, at a compound annual growth rate of 8.5%, according to research and consulting firm GlobalData.

The company’s latest report states that such robust growth can be attributed to the launch of efficacious pipeline products with convenient oral formulations or less frequent dosing than currently available products, an increase in treatment rates, and the continued awareness and recognition of ADHD in the adult age group.

Rachel Markwick, Ph.D., GlobalData’s analyst covering Neurology and Ophthalmology, said, “Currently, the ADHD market is rife with unmet needs. These include a need for more treatment options, clinically relevant head-to-head comparisons between current marketed and pipeline drugs, improved diagnostic tests, and increased education and recognition of ADHD.

“Late-stage pipeline treatments are anticipated to be a key driver in the ADHD market. Promising drugs include Supernus Pharmaceuticals’ SPN-810 (molindone hydrochloride ER), a late-stage pipeline drug designed to treat a particular set of symptoms that includes impulsive aggression, and Shire’s SHP-456, a late-stage pipeline asset designed to extend symptom coverage into the evening. SHP-456’s commercial success will be driven by the fact it has been formulated to last for 16 hours, whereas its predecessor, Adderall XR, lasts for only 12 hours.”

GlobalData expects that the ADHD market would readily open up to both new and existing drugs that address other unmet needs in this space, which include improved diagnostic rates and subsequent patient uptake across the 7MM.

Markwick continued: “The late-stage pipeline has a number of stimulant formulations that offer an increased number of options with more convenient dosage forms and extended coverage of ADHD symptoms. However, these stimulant candidate drugs are only seeking approval in the US market.

“The majority of the ADHD late-stage pipeline is populated with non-stimulant drugs. Should companies seek approval for these products within the rest of the 7MM, the unmet need of increased treatment options in these markets could be satisfied within the forecast period.”

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing